DURECT Corporation (DRRX)
- Previous Close
0.9100 - Open
0.9098 - Bid 0.6300 x 200
- Ask 1.2100 x 200
- Day's Range
0.9000 - 0.9188 - 52 Week Range
0.4700 - 7.4600 - Volume
4,347 - Avg. Volume
174,430 - Market Cap (intraday)
28.516M - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2000 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.75
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
www.durect.com58
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: DRRX
Performance Overview: DRRX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DRRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DRRX
Valuation Measures
Market Cap
28.24M
Enterprise Value
19.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.82
Price/Book (mrq)
1.91
Enterprise Value/Revenue
2.26
Enterprise Value/EBITDA
-0.78
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-43.79%
Return on Equity (ttm)
-138.93%
Revenue (ttm)
8.55M
Net Income Avi to Common (ttm)
-27.62M
Diluted EPS (ttm)
-1.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
29.68M
Total Debt/Equity (mrq)
140.34%
Levered Free Cash Flow (ttm)
-20.96M
Research Analysis: DRRX
Analyst Price Targets
Fair Value
Analyst Recommendations
Earnings
Research Reports: DRRX
Daily – Vickers Top Insider Picks for 08/04/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 08/02/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 06/16/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 06/07/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.